Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells

被引:26
作者
Yao, Yao [1 ,2 ,4 ]
Sun, Yueyue [1 ,2 ,4 ]
Shi, Min [1 ,2 ,4 ]
Xia, Dandan [1 ,2 ,4 ]
Zhao, Kai [1 ,2 ,4 ]
Zeng, Lingyu [1 ,2 ,4 ]
Yao, Ruosi [1 ,2 ,4 ]
Zhang, Ying [3 ]
Li, Zhenyu [2 ]
Niu, Mingshan [1 ,2 ,4 ]
Xu, Kailin [1 ,2 ,4 ]
机构
[1] Xuzhou Med Coll, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China
[2] Xuzhou Med Coll, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[3] Xuzhou Med Coll, Pathol Lab, Xuzhou, Jiangsu, Peoples R China
[4] Key Lab Bone Marrow Stem Cell, Xuzhou, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
multiple myeloma; STAT3; piperlongumine; bortezomib resistance; immunoproteasome; PROTEASOME; PROLIFERATION; ACTIVATION; IMMUNOPROTEASOME; DERIVATIVES; AUTOPHAGY; SURVIVAL; DEATH;
D O I
10.18632/oncotarget.11988
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Effective new therapies are urgently needed for the treatment of multiple myeloma (MM), an incurable hematological malignancy. In this study, we evaluated the effects of piperlongumine on MM cell proliferation both in vivo and in vitro. Piperlongumine inhibited the proliferation of MM cells by inducing cell apoptosis and blocking osteoclastogenesis. Notably, piperlongumine also reduced bortezomib resistance in MM cells. In a disseminated MM mouse model, piperlongumine prolonged the survival of tumor-bearing mice without causing any obvious toxicity. Mechanistically, piperlongumine inhibited the STAT3 signal pathway in MM cells by binding directly to the STAT3 Cys712 residue. These findings suggest that the clinical use of piperlongumine to overcome bortezomib resistance in MM should be evaluated.
引用
收藏
页码:73497 / 73508
页数:12
相关论文
共 40 条
[1]   The proteasome: a novel target for cancer chemotherapy [J].
Almond, JB ;
Cohen, GM .
LEUKEMIA, 2002, 16 (04) :433-443
[2]   Three-dimensional structure of the Stat3β homodimer bound to DNA [J].
Becker, S ;
Groner, B ;
Müller, CW .
NATURE, 1998, 394 (6689) :145-151
[3]  
Bharadwaj U., 2014, ONCOGENE
[4]   Proteasome inhibitor bortezomib for the treatment of multiple myeloma [J].
Cavo, M. .
LEUKEMIA, 2006, 20 (08) :1341-1352
[5]   Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP [J].
Chen, Yong ;
Liu, Ju Mei ;
Xiong, Xin Xin ;
Qiu, Xin Yao ;
Pan, Feng ;
Liu, Di ;
Lan, Shu Jue ;
Jin, Si ;
Yu, Shang Bin ;
Chen, Xiao Qian .
ONCOTARGET, 2015, 6 (08) :6406-6421
[6]  
Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO
[7]  
2-Q
[8]   Emerging therapies for the treatment of relapsed or refractory multiple myeloma [J].
Dimopoulos, Meletios A. ;
San-Miguel, Jesus F. ;
Anderson, Kenneth C. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) :1-15
[9]   Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF [J].
Ding, Jiang-hua ;
Yuan, Li-ya ;
Huang, Rui-Bin ;
Chen, Guo-an .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (04) :329-339
[10]   Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells [J].
Franke, N. E. ;
Niewerth, D. ;
Assaraf, Y. G. ;
van Meerloo, J. ;
Vojtekova, K. ;
van Zantwijk, C. H. ;
Zweegman, S. ;
Chan, E. T. ;
Kirk, C. J. ;
Geerke, D. P. ;
Schimmer, A. D. ;
Kaspers, G. J. L. ;
Jansen, G. ;
Cloos, J. .
LEUKEMIA, 2012, 26 (04) :757-768